NASDAQ:CNTX

Context Therapeutics Q1 2026 Earnings Results & Report

Context Therapeutics logo
$0.17 0.00 (-2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.17 +0.00 (+0.96%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Context Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 6, 2026. The company reported EPS of -$0.09 versus the -$0.12 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Context Therapeutics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Context Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Context Therapeutics Q1 2026 Earnings FAQ

Context Therapeutics (NASDAQ:CNTX) reported earnings of -$0.09 per share for Q1 2026, beating the consensus estimate of -$0.12. The report was announced on Wednesday, May 6, 2026.

Context Therapeutics Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Context Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email.

About Context Therapeutics

Context Therapeutics (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells.

Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors.

Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors. The company is based in the United States and conducts clinical-stage drug development.

View Context Therapeutics Profile